SCHEMBL2360187

SCHEMBL2360187

Oc1ccccc1-c1ncc2ccccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.56
MEN1 O00255 7/20 0.48
KMT2A Q03164 7/20 0.48
POLB P06746 3/20 0.48
MAPT P10636 3/20 0.48
TSHR P16473 2/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
SMAD3 P84022 1/20 0.44
ALK Q9UM73 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.43
NTRK1 P04629 1/20 0.43
GAA P10253 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17653988 0.84 CYP1A2 (0.51) CYP1A2MEN1KMT2AMAPTHPGD
SCHEMBL30900829 0.84 CYP1A2 (0.51) CYP1A2MEN1KMT2AMAPTHPGD
SCHEMBL8775741 0.84 CYP1A2 (0.44) CYP1A2MEN1KMT2APOLBMAPT
SCHEMBL6417704 0.81 PIK3CD (0.47) CYP1A2MEN1KMT2APOLBMAPT
SCHEMBL17654018 0.80 CYP1A2 (0.48) CYP1A2MEN1KMT2APOLBMAPT
SCHEMBL1672650 0.80 CYP1A2 (0.60) CYP1A2MAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL30198446 0.80 CYP1A2 (0.60) CYP1A2MAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL30527184 0.80 CYP1A2 (0.60) CYP1A2MAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL8776603 0.78 CYP1A2 (0.40) CYP1A2MEN1KMT2APOLBMAPT
SCHEMBL5788551 0.78 CYP1A2 (0.56) CYP1A2MEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843867-A novel compounds and their use for detecting target molecules in a sample 日内瓦大学 2019-06-04 CN claimed
CN-108732151-B Preparation of luminescent gold nanoparticles with high-sensitivity optical response to volatile amine and rapid analysis and detection method thereof 华南理工大学 2021-01-19 CN disclosed
US-10619098-B2 Ultraviolet light absorbers TRANSITIONS OPTICAL, INC. (US) 2020-04-14 US disclosed
CN-106893579-B A kind of fluorescence probe and preparation method and purposes with aggregation-induced emission property 华南理工大学 2019-07-12 CN disclosed
CN-109843867-A novel compounds and their use for detecting target molecules in a sample 日内瓦大学 2019-06-04 CN disclosed
CN-108732151-A There is the preparation of luminous gold nanoparticle and its rapid analysis and test method of highly sensitive optic response for volatile amine 华南理工大学 2018-11-02 CN disclosed
EP-3201292-B1 ULTRAVIOLET LIGHT ABSORBERS TRANSITIONS OPTICAL INC (US) 2018-08-01 EP disclosed
CN-107573926-A A kind of double luminous organic fluorescence temperature sensing films and preparation method 南京邮电大学 2018-01-12 CN disclosed
US-20170275534-A1 ULTRAVIOLET LIGHT ABSORBERS TRANSITIONS OPTICAL, INC. 2017-09-28 US disclosed
US-20170275534-A1 ULTRAVIOLET LIGHT ABSORBERS TRANSITIONS OPTICAL, INC. 2017-09-28 US disclosed
CN-106893579-A A kind of fluorescence probe and preparation method and purposes with aggregation-induced emission property 华南理工大学 2017-06-27 CN disclosed
US-8324226-B2 Therapeutic oxy-phenyl-aryl compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-12-04 US disclosed
EP-2227460-B1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER REC TECH LTD (GB) 2012-06-20 EP disclosed
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-08-18 US disclosed
EP-2227460-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2010-09-15 EP disclosed
WO-2009053694-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-30 WO disclosed
US-4639454-A LYMPHOID LEUKEMIA E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10619098-B2 Ultraviolet light absorbers ERCC1, MCM4, ERCC4 CYP1A2 477/4885MEN1 36/4885KMT2A 2831/4885
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CHEK2, CHEK1, PLK1 CYP1A2 1846/4885MEN1 4617/4885KMT2A 1061/4885
US-20170275534-A1 ULTRAVIOLET LIGHT ABSORBERS MCM4, ERCC1, ERCC4 CYP1A2 358/4885MEN1 35/4885KMT2A 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.